Market Overview:
The global CAR-T cell immunotherapies for cancer market is expected to grow at a CAGR of XX% during the forecast period 2018-2030. The market growth can be attributed to factors such as increasing incidence of cancer, technological advancements in CAR-T cell therapy and rising demand for personalized medicine. However, the high cost associated with CAR-T cell therapy is likely to restrain the growth of this market during the forecast period. The global CAR-T cell immunotherapies for cancer market by type is segmented into CD19 targetingCAR T cells, BCMA targetingCAR T cells and EPCAM targetingCAR T cells. The CD19 targetingCAR T cells segment is expected to account for the largest share of the global CAR-T cell immunotherapies for cancer market by 2021 owing to its high efficacy in treating hematological cancers such as leukemia and lymphoma. The BCMA targetingCAR T cells segment is projected to grow at a highest CAGR from 2016to 2021 owing to its growing use in treating multiple myeloma patients. Oncology disorders are classified into three types: hematological cancers, solid tumors.
Product Definition:
CAR-T cell immunotherapies are a form of cancer treatment that uses genetically modified T cells to attack cancer cells. These therapies are important because they can be customized to target the specific cancer affecting each individual patient.
Global CAR-T Cell Immunotherapies for Cancer Market Size Growth Rate by Target Antigen: 2016 VS 2021 VS 2027:
The global CAR-T cell immunotherapies for cancer market size was valued at USD 3.6 billion in 2016 and is expected to grow at a CAGR of XX% over the forecast period. The key factors responsible for its growth include increasing adoption of precision medicine, stem cell therapy, and high R&D investments by the major players in this sector.
CD19:
CD19 is a protein that acts as an antigen for B-cell generation. It is found on the surface of most B-cell types, but certain T-cell types recognize it as an antibody target. The body’s immune system normally makes antibodies to fight infections and diseases; however, sometimes the antibodies can mistakenly attack healthy cells.
Application Insights:
The other oncological disorders segment dominated the global market in terms of revenue share in 2020 owing to an increase in the incidence of non-small cell lung cancer and pancreatic cancer. Non-small cell lung cancer is also known as small cell or non-smokers¢â‚¬â„¢ Lung Cancer. According to the American Cancer Society, around 80% of all NSCLC cases are diagnosed after 75 years of age.
Solid tumors accounted for a significant share due to increasing incidence rates for various solid tumor types such as breast carcinoma, colorectal carcinoma, prostate carcinoma and melanoma. The introduction of new treatment options such as immunotherapy along with chemotherapy has led to improved outcomes for patients suffering from advanced cancers including metastatic breast carcinoma and refractory metastatic prostate carcinoma which were previously untreatable leading to increased adoption across various regions worldwide over recent years (Hematological malignancies).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, such as Kite Pharma, Inc., Novartis AG, and Stryker. These companies are engaged in research activities that focus on development of novel therapies for treatment of cancer using CAR-T cells. Moreover, these companies are involved in various initiatives that aim at increasing adoption rate of this technology across North America and Europe region.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is one of the key growth drivers for the CAR-T cell immunotherapies for cancer market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 600,920 people will die from this disease. This number is expected to rise in the coming years due to factors such as aging population and lifestyle changes. This will create a high demand for novel therapies such as CAR-T cell immunotherapies and drive the growth of this market during the forecast period.
- Rising awareness about CAR-T cell immunotherapy: The rising awareness about CAR-T cell immunotherapy among patients and healthcare professionals is another major driver for this market’s growth during the forecast period 2017 – 2025 . There has been an increase in clinical trials involving various types of cancers which are being conducted globally with promising results that are likely to create a positive impact on patient outcomes owing to increased adoption rates over traditional chemotherapy treatments or radiation therapy options available currently..
Scope Of The Report
Report Attributes
Report Details
Report Title
CAR-T Cell Immunotherapies for Cancer Market Research Report
By Type
Global CAR-T Cell Immunotherapies for Cancer Market Size Growth Rate by Target Antigen: 2016 VS 2021 VS 2027, CD19, BCMA, EPCAM
By Application
Hematological Cancer, Solid Tumor, Other Oncological Disorders
By Companies
NOVARTIS, Penn, Fosun Pharma, Celgene Corporation, Legend Biotech, SHEBA, JW Therapeutics, Protheragen, EXUMA Biotechnology
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
140
Number of Tables & Figures
98
Customization Available
Yes, the report can be customized as per your need.
Global CAR-T Cell Immunotherapies for Cancer Market Report Segments:
The global CAR-T Cell Immunotherapies for Cancer market is segmented on the basis of:
Types
Global CAR-T Cell Immunotherapies for Cancer Market Size Growth Rate by Target Antigen: 2016 VS 2021 VS 2027, CD19, BCMA, EPCAM
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hematological Cancer, Solid Tumor, Other Oncological Disorders
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- NOVARTIS
- Penn
- Fosun Pharma
- Celgene Corporation
- Legend Biotech
- SHEBA
- JW Therapeutics
- Protheragen
- EXUMA Biotechnology
Highlights of The CAR-T Cell Immunotherapies for Cancer Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Global CAR-T Cell Immunotherapies for Cancer Market Size Growth Rate by Target Antigen: 2016 VS 2021 VS 2027
- CD19
- BCMA
- EPCAM
- By Application:
- Hematological Cancer
- Solid Tumor
- Other Oncological Disorders
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the CAR-T Cell Immunotherapies for Cancer Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
CAR-T cell immunotherapies are treatments that use a patient’s own immune cells to fight cancer. These treatments work by helping the immune system recognize and attack cancer cells.
Some of the major players in the car-t cell immunotherapies for cancer market are NOVARTIS, Penn, Fosun Pharma, Celgene Corporation, Legend Biotech, SHEBA, JW Therapeutics, Protheragen, EXUMA Biotechnology.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 CAR-T Cell Immunotherapies for Cancer Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 CAR-T Cell Immunotherapies for Cancer Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 CAR-T Cell Immunotherapies for Cancer Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the CAR-T Cell Immunotherapies for Cancer Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global CAR-T Cell Immunotherapies for Cancer Market Size & Forecast, 2020-2028
4.5.1 CAR-T Cell Immunotherapies for Cancer Market Size and Y-o-Y Growth
4.5.2 CAR-T Cell Immunotherapies for Cancer Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Global CAR-T Cell Immunotherapies for Cancer Market Size Growth Rate by Target Antigen: 2016 VS 2021 VS 2027
5.2.2 CD19
5.2.3 BCMA
5.2.4 EPCAM
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hematological Cancer
6.2.2 Solid Tumor
6.2.3 Other Oncological Disorders
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global CAR-T Cell Immunotherapies for Cancer Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 CAR-T Cell Immunotherapies for Cancer Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Global CAR-T Cell Immunotherapies for Cancer Market Size Growth Rate by Target Antigen: 2016 VS 2021 VS 2027
9.6.2 CD19
9.6.3 BCMA
9.6.4 EPCAM
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hematological Cancer
9.10.2 Solid Tumor
9.10.3 Other Oncological Disorders
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Global CAR-T Cell Immunotherapies for Cancer Market Size Growth Rate by Target Antigen: 2016 VS 2021 VS 2027
10.6.2 CD19
10.6.3 BCMA
10.6.4 EPCAM
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hematological Cancer
10.10.2 Solid Tumor
10.10.3 Other Oncological Disorders
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Global CAR-T Cell Immunotherapies for Cancer Market Size Growth Rate by Target Antigen: 2016 VS 2021 VS 2027
11.6.2 CD19
11.6.3 BCMA
11.6.4 EPCAM
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hematological Cancer
11.10.2 Solid Tumor
11.10.3 Other Oncological Disorders
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Global CAR-T Cell Immunotherapies for Cancer Market Size Growth Rate by Target Antigen: 2016 VS 2021 VS 2027
12.6.2 CD19
12.6.3 BCMA
12.6.4 EPCAM
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hematological Cancer
12.10.2 Solid Tumor
12.10.3 Other Oncological Disorders
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Global CAR-T Cell Immunotherapies for Cancer Market Size Growth Rate by Target Antigen: 2016 VS 2021 VS 2027
13.6.2 CD19
13.6.3 BCMA
13.6.4 EPCAM
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hematological Cancer
13.10.2 Solid Tumor
13.10.3 Other Oncological Disorders
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 CAR-T Cell Immunotherapies for Cancer Market: Competitive Dashboard
14.2 Global CAR-T Cell Immunotherapies for Cancer Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 NOVARTIS
14.3.2 Penn
14.3.3 Fosun Pharma
14.3.4 Celgene Corporation
14.3.5 Legend Biotech
14.3.6 SHEBA
14.3.7 JW Therapeutics
14.3.8 Protheragen
14.3.9 EXUMA Biotechnology
